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Abstract 
Survival rates for ovarian cancer have remained relatively stable for the past two 
decades, despite advances in surgical techniques and cytotoxic chemotherapeutics, 
indicating a requirement for better therapies.  One pathway currently proposed for 
targeting is the HGF/cMET pathway.  Up-regulated in a number of tumour types, 
cMET is a tyrosine kinase receptor expressed on epithelial cells.  In ovarian cancer, it 
has been identified as highly expressed in the four major subtypes, with expression 
estimates ranging from 11-68% of cases.  HGF, the only known ligand for cMET, is 
found at high levels in both serum and ascites in women with ovarian cancer, and 
proposed to induce both migration and metastasis.  However, clinically validated 
biomarkers are not yet available for either HGF or cMET, preventing a clear 
understanding of the true rate of over-expression, or its correlation with prognosis.  
Despite this, a number of agents against HGF and cMET are currently being 
investigated in clinical trials for multiple tumour types, including ovarian.   However, 
a lack of patient selection, biomarker usage, and post-hoc analysis correlating 
response with expression, has resulted in the majority of these trials showing little 
beneficial effect from these agents, indicating that additional research is required to 
determine their usefulness in patients with ovarian cancer.  
 
Bullet points 
• In the absence of clinically validated biomarkers, the frequency of high 
HGF/cMET signalling is unknown. 
• Therefore it is not possible to correlate prognosis 
• HGF/cMET-targeted therapies are being used without knowing whom they 
will benefit.  
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1. Introduction 
Ovarian cancer is the deadliest of the gynaecological malignancies, and is the 5th 
commonest cause of cancer-related deaths in women [1].  Survival rates for epithelial 
ovarian cancer (EOC), which accounts for 90% of ovarian cancer diagnoses, have 
remained relatively stable for the past two decades, despite advances in surgical 
options and chemotherapeutics.   
1.1 Classification of EOC 
In recent years, EOC has been classified as being of Type I or Type II, with the 
former being described as being indolent, and on a molecular trajectory from benign 
to atypical proliferative through to invasive tumours.  These Type I lesions typically 
remain within the ovary, and are classified as genomically stable, without TP53 
mutations, and comprise the low-grade serous-papillary, endometrioid, clear cell, 
mucinous, tumours, and borderline tumours of low malignant potential  [2].  Type II 
EOC, on the other hand, are thought to be de novo aggressive, and are frequently 
diagnosed when metastases are already present.  They are genetically unstable, and 
universally contain TP53 mutations and dysfunctional breast cancer genes, BRCA1/2, 
(which results in further chromosomal disruption).  Their origin has long been 
debated, but current evidence points to the secretory epithelium of the distal fallopian 
tube (reviewed in [2, 3]).   High grade serous carcinomas, high grade endometrioid, 
and undifferentiated carcinomas [2] are classified as type II epithelial ovarian cancers. 
Overall survival rates for the two types differ dramatically, with median survival 
being 82 months [4] versus 30 months [5] for Types I and II, respectively.  This 
difference is despite the initial sensitivity of type II tumours to standard carboplatin 
and paclitaxel chemotherapy.  However, a recent study performed by Panici and 
colleagues suggest that the survival between the two groups to be far closer (72 
months vs 62 for types I and II respectively [6]), indicating that there is still much we 
don’t understand about this disease.  Adding to this argument, is the finding that clear 
cell ovarian cancer (CCOC) is genetically separate to other forms of ovarian cancer, 
with different common mutations [7], and de novo chemo-resistance.  
Ongoing molecular characterisation and genetic studies suggests that this model may 
be overly simplistic, with a number of subtypes being re-classified, or further divided 
into additional sub-groups [8,	   9,	   7,	   10].  These new subtypes demonstrate different 
genetic lesions and transcriptional profiles, chemo-sensitivity, and survival rates, 
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indicating a need to incorporate this information into treatment plans for ovarian 
cancer. 
1.2 Current treatment of patients with EOC 
Currently, most women diagnosed with ovarian cancer, regardless of subtype or Type, 
undergo total abdominal hysterectomy (TAH), bilateral salpingo-oophorectomy 
(BSO), and omentectomy surgery, to remove the ovaries, fallopian tubes, uterus and 
omentum.  In cases of advanced ovarian cancer, debulking of all other visible tumour 
deposits is also performed with the aim of achieving complete macroscopic clearance 
of disease.  Patients are usually treated with a cytotoxic chemotherapy post-surgery, 
invariably a platinum based regimen. For women with advanced disease (stage 3C/4) 
at presentation, initial treatment with chemotherapy can be undertaken prior to 
surgery, which can reduce surgical morbibity but does not improve overall survival [11].	  	  Despite this invasive surgery and treatment, the majority of women recur within 
2 years [12].   
In recent years, as a better understanding of the molecular landscape of EOC has 
become available, a number of targeted therapies have been proposed and trialled.     
 
2. HGF/cMET in the ovary 
A pathway attracting attention as a potential target in ovarian cancer is the 
HGF/cMET axis.  cMET is a receptor tyrosine kinase, typically expressed on 
epithelial cells, and is present in both embryonic and adult ovarian tissue [13, 14] .  
HGF (hepatocyte growth factor), the only known ligand for cMET, is expressed on 
cells of mesenchymal origin, and acts as an epithelial cell mitogen, motogen, and 
morphogen.  During ovarian development, HGF is produced by mesenchyme within 
the uro-genital ridge adjacent to cMET-expressing epithelial cells, suggesting an 
involvement of this pathway in ovarian development and proliferation [15].  Paracrine 
signalling between the ligand and receptor has also been demonstrated during the 
development of the ovary and follicles [16-19].  In the adult ovary, the ovarian surface 
epithelium and granulosa cells express cMET, while the stroma and theca cells 
produce HGF [20].  HGF expression is also regulated by a number of ovarian 
hormones [21, 18], indicating a role for this signalling axis in oocyte maturation. 
2.1 HGF/cMET in ovarian cancer 
In recent years, mis-regulation of the HGF/cMET pathway has been investigated in 
ovarian cancer, and high expression of cMET has been identified in subsets of all four 
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major histotypes of EOC (high grade serous, clear cell, mucinous, and endometrioid  
[22-29]).  It must be noted, however, that the outcome from this over-expression 
remains unclear.  While several studies have demonstrated a correlation between high 
cMET expression and poor prognosis [25, 30], others have shown no statistically 
significant correlation between cMET expression and shorter survival [26, 29], and 
still others suggest that cMET is expressed in early tumours, and is associated with 
good prognostic factors [23].  It should be noted that the majority of these studies 
were performed on relatively small numbers of samples, and usually contained mixed 
subtypes of EOC, thus further confusing the matter.  These findings are summarised 
in Table 1. 
High levels of the cMET ligand, HGF, in serum in women presenting with a pelvic 
mass is indicative of ovarian cancer (>2 SD above serum levels in women with benign 
ovarian tumours), and is predictive of poor prognosis in women with advanced EOC 
[31].  HGF is also present at high levels in the ascites of patients with ovarian cancer 
[32] [33], and is proposed to induce ovarian carcinoma cell migration and metastasis.  
Similarly, high expression of HGF in tumour cells has been correlated to decreased 
progression-free survival, and higher serum CA-125 and CA19-9 levels [34]. While 
HGF is typically expressed in the stroma, in ovarian cancer samples, it appears to be 
expressed in the epithelial cells [29, 35, 19, 32], potentially generating an autocrine 
loop.  However, it has been previously noted that HGF can regulate its own 
expression [36] as well as that of cMET [37], setting in place an auto-amplification 
loop, and it is possible that one of the early steps of ovarian carcinogenesis is the co-
expression of HGF and cMET in ovarian surface epithelium.  This is supported by 
evidence showing that cultures of ovarian surface epithelium (OSE) from women with 
a family history of ovarian cancer express both HGF and cMET, whereas similar 
cultures from women with no family history do not [38], although how this pertains to 
the fallopian tube origin of ovarian cancer is yet to be ascertained.  This autocrine 
loop is most likely then perpetuated by the high expression of HGF within the ascites 
fluid [32, 33]. HGF present in ascites also impacts the mesothelial cells of the 
peritoneum, inducing a mesothelial-to-mesenchymal transition (MMT), which may 
provide a more favourable environment for ovarian cancer cells to colonise and 
invade [34].    Kenny et al. demonstrated that ovarian cancer cells preferentially 
adhered to omental fibroblasts rather than mesothelial cells [39], which may explain 
the increased adhesion in the presence of HGF, where MMT has been induced, and 
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HGF enhances the adhesion of ovarian cancer cells to mouse peritoneum [40].  
Interestingly, use of a HGF-neutralising antibody in a mouse model of ovarian 
peritoneal metastasis resulted in decreased tumour cell dissemination and ascites 
formation [34], adding further weight to the logic in targeting the HGF/cMET axis in 
ovarian cancer. Data is currently accumulating that clear cell ovarian cancer in 
particular displays a high rate of cMET expression, and specific MET gene 
amplification [41-­‐44].  Given this subtype’s poor prognosis, chemo-resistance, and its 
genetic separation from other forms of ovarian cancer, subtype-specific treatment 
merits further investigation. 
 
3. Mis-regulation mechanisms of HGF/cMET 
cMET was originally identified as an oncogene as a result of a chromosomal 
rearrangement that fused the translocating promoter region (tpr) to the cMET kinase 
domain [45].  The same rearrangement has since been identified in precursor lesions 
of gastric cancer, suggesting that it can pre-dispose to the development of gastric 
carcinomas [46].  Unlike the majority of oncogenes, mutations within the kinase 
domain of cMET are not frequent, although mutations have been found outside of the 
kinase domain (reviewed in [47]).  Amplification of the cMET gene, or polysomy (of 
chromosome 7) is detected in a number of cancer types, and has been correlated with 
poor prognosis, high protein expression, and ligand-independent activation of Met 
(reviewed in [47]).  As yet, there is no clinically validated method for defining cMET 
amplification, and thus the actual rate of amplification in tumour samples varies 
significantly between studies. The correlation between sensitivity to cMET-inhibitory 
agents and cMET amplification remains unclear, with various studies reporting 
correlation [48-51], transient sensitivity [52], or no correlation [53-55], and as such it 
will be important to define a method by which copy number can be accurately 
determined and clinically validated.  In high grade serous ovarian cancer, the TCGA 
cBioPortal [56,	  57]	  reveals mutations in the Met gene to be present in 1.3% of cases, 
and amplifications in 1.6%.  However, neither mutation nor amplification was 
associated with survival.  High cMET expression has also been noted in the absence 
of mutation or amplification, most likely a result of transcriptional up-regulation.  A 
number of factors are known to result in increases in cMET expression, including 
hypoxia [58], and activation of other oncogenes, such as Ras and Ret [59].   
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HGF is rarely found to be mutated or amplified in cancer, and a search of the TCGA 
cBioPortal [56,	  57]	  reveals HGF to be mutated in 0.6% of high grade serous ovarian 
cancer patients (with mutations resulting in truncation), and amplified in 1.3% of 
cases.  Although an association between the rs1800793 single nucleotide 
polymorphism and ovarian cancer mortality has been identified, this did not correlate 
with changes in protein or mRNA expression [29].  However, transcriptional up-
regulation has been observed resulting from Stat-3 and c-Src expression [60], and the 
co-expression of HGF and cMET in tumour cells can drive autocrine activation, as 
well as increased transcription for both genes.  A number of studies have identified 
that HGF expression and autocrine cMET activation decreases sensitivity to cMET 
inhibitors, and stromal HGF levels have been linked to clinical responses in patients 
treated with the anti-HGF agent, ficlatuzumab [61-63], demonstrating the importance 
of the use of biomarkers in predicting clinical responses.   
In the absence of ligand, cMET can also be activated by integrin interaction, the 
hyaluronan receptor CD44, plexins, and interaction with other receptor tyrosine 
kinases such as EGFR, RET, & Ron kinase, and some G protein coupled receptors 
[64-68], indicating that it may be necessary to use cMET inhibitors in combination 
with other agents. 
 
4. Therapeutic agents against HGF/cMET 
A number of therapeutic agents targeting HGF or cMET have been evaluated in pre-
clinical cancer models or clinical trials for various solid cancers in recent years, with 
varying levels of success.  Broadly, these agents fall into two categories: either 
antibodies targeting HGF or cMET, the majority of which prevent ligand-receptor 
interaction; or small molecule inhibitors, typically designed to block phosphorylation 
of cMET, and thus prevent downstream signalling.  Gene therapy using adenoviruses 
expressing HGF-antagonist intra-molecules is also under investigation in patients  [69].  Details of agents recently in clinical trials are detailed in Table 2.  It has 
become apparent in recent years that single targeted drug therapy is usually 
ineffective, and frequently results in resistance.  As such, it may ultimately be 
necessary to combine anti-HGF/cMET therapeutics with additional agents, such as 
those targeting EGFR, PI3K/Akt/mTOR, or MEK/ERK pathways.  However, the 
efficacy and target population of anti-HGF/cMET agents must be defined first. 
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Clinical trials were traditionally designed to test agents which were assumed to have 
the same effect on all individuals, most recently cytotoxic chemotherapeutics 
targeting generic disease mechanisms.  Such trials are most efficacious when they 
assess a potential therapeutic effect that is about the same size or slightly smaller than 
the effect of the natural variation that exists between individuals [70].  One of the 
surprising details to come out of recent trials using HGF or cMET targeting agents is 
the absence of patient selection using biomarkers, or indeed correlation of results 
post-hoc, with HGF/Met expression.   
4.1 HGF/cMET therapeutics in ovarian cancer 
While few of the phase I trials have included patients with ovarian cancer (see Table 3 
and below), these have been sufficiently promising to merit a phase II trial using 
rilotumumab in patients with recurrent epithelial ovarian, fallopian tube, or primary 
peritoneal carcinoma [71](NCT01039207).  However, using primary endpoints of 
tumour response and six-month progression-free survival, and secondary endpoints of 
progression-free and overall survival, this study concluded that, although 
rilotumumab was well tolerated, it had limited activity, and would not be investigated 
further as a single agent.  The authors of the study conclude that use of predictive 
biomarkers might guide a more targeted approach to treatment in the future, 
highlighting a recurring theme in the use of both cMET- and HGF- targeted agents. 
 
5. Biomarkers for the HGF/cMET pathway 
Although a number of studies have attempted to define biomarkers for over-activation 
of the cMET pathway, no clinically validated tests are currently available.  
Immunohistochemical staining for cMET and phosphorylated cMET, quantitative RT-
PCR for Met and HGF, and gene amplification of Met, have all been reported in the 
literature as potential biomarkers for selection of patients who may benefit from 
HGF/cMET-targeting agents.  However, the variation in reported incidences of over-
expression/amplification within similar cohorts of patients confirm the need for 
carefully validated assays.   
5.1 IHC for cMET 
Estimates of the frequency of HGF/cMET dysregulation differs between tumour 
types, but even within individual tumour types, there exists a wide variation in the 
reported frequency.  For example, recent IHC studies performed on gastric tumour 
samples have reported cMET over-expression in 4-63% of cases [72-77] and various 
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studies performed in ovarian cancer estimate high expression of cMET to be present 
in 11-68 % of cases [30, 22, 23, 26, 25] (Table 1).  The majority of the estimates 
above come from IHC studies, using a number of different antibodies, but no 
consensus on scoring criteria yet exists, nor whether cytoplasmic or membranous 
staining for cMET is important.  Work performed by Koeppen and colleagues has 
described the validation of the CONFIRM anti-total cMET (SP44) rabbit monoclonal 
antibody on formalin-fixed paraffin-embedded tissue as part of the phase II trial 
testing onartuzumab in non-small cell lung cancer [78].  Using cell lines with known 
levels of cMET expression, comparisons between SP44 antibody staining, flow 
cytometry (using a different anti-Met antibody), and mRNA levels, it was determined 
that the SP44 antibody specifically recognises cMET, and not the closely-related Ron 
receptor.  Furthermore, a comprehensive clinical scoring system was determined, 
which enabled a cut-off of 50% (of cells stained moderate/strong) to be utilised in the 
trial to differentiate patient outcomes when treated with onartuzumab [78].  A number 
of additional antibodies (D1C2, and A2H2-3) have also shown promise for use in 
clinical studies for detection of cMET levels. However, additional validation on larger 
cohorts of clinically annotated samples will be required prior to their incorporation 
into clinical practice (Koeppen et al, ASCO 2014, abstract 11103, and [79]). 
5.2 Gene amplification and copy number of Met 
Other studies have used gene amplification (GA) or gene copy number (GCN) to 
determine if cMET has been amplified (either the gene itself, or larger portions of 
chromosome 7) [80, 81, 73, 78] although the usefulness of cMET genetic 
amplification as a biomarker, and its correlation to drug sensitivity, has yet to be 
validated in large scale trials.  Similarly, the correlation between copy number, 
protein expression level, and responsiveness to cMET-inhibitory agents is still under 
investigation [78].    
5.3 Phosphorylated cMET 
In a number of cancer types, including ovarian, amplification and mutation of cMET 
are relatively rare, making expression or activation (phosphorylation) a better readout 
of activity of the receptor.  Although a number of studies have incorporated staining 
for phosphorylated cMET, it is rare that samples both pre and post-treatment are 
available, and not yet clear that a reduction in IHC signal with treatment correlates to 
a therapeutic response in the patient.  Eder and Yap and colleagues both showed 
decreases in phosphorylated c-Met in tumour samples after treatment, although the 
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best patient responses identified were stable disease [82, 83].  Adding to the 
complexity of this matter is the labile nature of the phospho group (and indeed many 
other post-translational modifications), and its preservation in formalin-fixed paraffin-
embedded tissue.  A number of studies have demonstrated that proteins are rapidly de-
phosphorylated upon oxygen deprivation, with the majority of phosphoproteins being 
lost if not fixed within 60 minutes [84,	  85].	  Additionally,	   the	  stability	  of	  different	  phsopho-­‐epitopes	   is	   proposed	   to	   vary,	   both	   within	   a	   single	   tumour	   type,	   and	  between	   tissue	   types	   [86]	   making	   scoring	   and/or	   quantification	   of	   phospho-­‐antibody	  signals	  inherently	  difficult.	   	  All	  of	  these	  factors	  decrease	  the	  reliability	  of	   phospho-­‐cMET	   as	   a	   reliable	   biomarker	   for	   over-­‐activation	   of	   the	   pathway,	  making	   selection	   of	   patients	   for	   anti-­‐HGF/cMET	   targeted	   therapies	   more	  difficult.	   	   It	   should	   be	   noted	   that	   these	   difficulties	   are	   not	   unique	   to	   the	  HGF/cMET	  pathway,	  but	  applicable	  to	  increasing	  numbers	  of	  therapeutics	  which	  target	   pathways	   up-­‐regulated	   in	   cancer	   cells,	   many	   of	   which	   are	   defined	   by	  phospho-­‐activation	  rather	  than	  intrinsic	  genetic	  lesions. 
5.4 Circulating HGF 
While circulating HGF has been reported as elevated in patients with cancer in a 
number of studies, its use as a biomarker is still under investigation.  Both 
onartuzumab and ficlatuzumab, therapeutic antibodies directed against HGF, stabilise 
the protein, and cause increases in the serum with treatment [87, 61, 88].  This enables 
circulating HGF to be used as a pharmacodynamic marker for these agents, but 
perhaps not as a catch-all predictive biomarker for selecting patients for HGF/cMET 
therapies.  Furthermore, elevated HGF levels are observed in a number of disease 
settings, including virus/bacterial infections, graft-versus-host disease, and following 
surgical procedures, making their use as a biomarker for selection of patients less 
favourable [89-91].  It is also yet to be vigorously validated how circulating HGF 
levels relate to HGF levels within the tumour micro-environment [92].  Because HGF 
is a secreted, soluble, factor, it must be noted that HGF within the tumour tissue may 
not have been generated locally. 
5.5 A requirement for biomarkers 
Confusing the biomarker discussion is the finding that two patients with alveolar soft 
tissue sarcoma, whose archival tumour tissue was negative for c-Met IHC, and who 
have been treated with tivantinib, a cMET inhibitor, for >3 years, have maintained 
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stable disease for that period [93].  This may indicate that additional biomarkers need 
to be identified, or that fresh tumour biopsies need to be acquired prior to treatment 
commencement, to assess the cMET status more accurately, or that cMET-
independent actions of tivantinib are involved [94]. 
 
Recently, the need for biomarkers when targeting the HGF/cMET pathway has 
become apparent, with the finding that patients with NSCLC with low Met expression 
do worse when receiving onartuzumab (a monoclonal antibody targeting Met) + 
erlotinib than erlotinib + placebo [95].  It was proposed by Spigel and colleagues that 
dual inhibition of EGFR (by erlotinib) and Met might have different consequences in 
tumours with lower versus higher Met expression, such that this effect may only be 
seen on a back ground of EGFR inhibition.  However, a similar finding was reported 
in a study utilising rilotumumab (AMG 102, an anti-HGF monoclonal antibody) in 
metastatic gastric or esophagogastric junction cancer (Oliner, et al., ASCO 2012, 
abstract 4005).  It should be noted however, that the final study report for this trial 
[96] showed no difference in progression free- or overall- survival between Met low 
patients receiving rilotumumab  + chemotherapy, or chemotherapy alone.    
 
What is becoming quite apparent, is that not everyone may benefit from receiving 
targeted therapies such as those against HGF/cMET, and, dismayingly, some 
receiving the therapy may in fact do worse than those receiving placebo.  This makes 
it imperative to determine the population who will benefit, and thus to incorporate 
appropriate biomarkers into all studies moving forward.  For ovarian cancer, which is 
typically diagnosed late, and where the opportunity for 2nd line treatment is limited, it 
is vital that only patients who will potentially benefit from an agent receive it. 
 
6. HGF/cMET inhibitors trials in ovarian cancer 
As described above, the only study with results available addressing the use of agents 
targeting HGF/cMET in ovarian cancer is that in which patients with persistent or 
recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer 
were treated with rilotumumab (NCT01039207) [71].  This trial was stopped in the 
first phase of recruitment, due to a lack of sufficient positive results to progress to the 
second phase of the trial.  Of the 31 patients treated, 1 achieved a complete response, 
and six experienced stable disease (all patients had previously received platinum-
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based therapy).  However, surprisingly, no biomarkers were used, nor were analyses 
performed post-hoc on patients responding to treatment.  With current estimates of 
high cMET expression occurring in 11-68% of ovarian cancer cases (see Table 1) [30, 
22, 23, 26, 25], it is possible that as few as 3 patients enrolled within the study were in 
a position to benefit from receiving the anti-HGF antibody, and that as many as 29 
patients potentially to do worse upon receiving the therapy.    
Interestingly, a number of phase I trials of HGF/cMET targeting agents have included 
patients with ovarian cancer, [82, 97, 88, 54, 98, 61] several of which have reported 
favourable responses, with some correlated to biomarkers.   Preliminary data 
presented by Buckanovich and colleagues (Buckanovich et al, ASCO 2011, abstract 
5008) described a phase II discontinuation trial which had been halted due to high 
clinical activity seen in women with ovarian cancer treated with cabozantinib, a dual 
cMET and VEGFR2 inhibitor, although these data are yet to be published.  However, 
there are ongoing trials with cabozantinib directed at women with recurrent, 
progressive, or persistent, epithelial ovarian, fallopian tube, or peritoneal cancer 
(NCT02315430 and NCT01716715).                        
 6.1 Biomarker-based clinical trials                                                                                                   
With relatively small numbers of individuals likely to benefit from targeted therapies, 
such as those against the HGF/cMET pathway, it may prove more efficacious to 
utilise biomarker-based trials (rather than trials based on the primary site of a tumour), 
such as the recent NCI Molecular Analysis for Therapy Choice (MATCH) trial, in 
which more than 200 actionable mutations/amplifications/translocations were 
assessed, and patients were matched to investigational drugs directed to the lesion of 
interest that their tumour harboured.  Although randomised clinical trials remain the 
gold standard for assessing the efficacy of new agents, their design is not 
feasible/optimal time- or expense- wise for patients with rapidly advancing 
malignancies, or for agents designed against mutations present in a small proportion 
of the population. 
 
7. Conclusions and recommendations 
There is an urgent need to identify new therapeutics for patients with ovarian cancer, 
and the HGF/cMET signalling pathway merits further investigation.  However, there 
are a number of factors that need to be addressed in order to assess the utility and 
efficacy of such therapeutics.  First and foremost is the requirement for good 
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biomarker/s that can be used clinically, such that the true percentage of patients with 
each subtype of EOC exhibiting high HGF or cMET activity can be assessed.  This 
will require the use of large sample sizes, and agreement as to how to score such 
samples.  However, in recent years, IHC assays to determine HER2 status in various 
cancers have been successfully implemented clinically, and are now used as 
determinants for treatments in breast and gastric cancer.  It seems likely that IHC will 
be used, as amplifications and mutations are relatively rare, and to date, little 
correlation has been seen between amplification, protein expression, and sensitivity to 
inhibitors.  Using a validated system to measure cMET will also enable retrospective 
analyses as to the prognostic value of expression.  Of grave importance is determining 
the consequences of treating individuals with low cMET expression with cMET 
inhibitors, and again, this will require the incorporation of biomarkers into ongoing 
trials, and should be a requirement for enrolment in the first instance.    
Small molecule inhibitors and therapeutic antibodies have the potential to change 
treatment options and survival rates in many cancers.  However, these agents are 
designed to target particular genetic lesions or specific aberrations in signalling 
pathways, and thus it is logical, and likely to only be of benefit to, individuals 
harbouring the lesions/signalling aberrations against which the agents are designed.  
In order to accomplish this, it is imperative that we utilise biomarkers to both identify 
such patients, and to be able to determine the usefulness of such agents in these 
patients. 
 
Acknowledgements	  The	  author	  would	  like	  to	  thank	  Prof.	  Iain	  McNeish	  and	  Darren	  Ennis	  for	  their	  helpful	  comments	  in	  reviewing	  this	  manuscript.	  	  
Compliance	  with	  Ethical	  Standards	  
Conflict	  of	  Interest	  The	  author,	  KMJ,	  declares	  no	  conflicts	  of	  interest	  
Funding	  
Salary support is provided by a Wellcome Senior Research Fellowship 
(103721/Z/14/Z) held by Andrew Biankin. 
	   	  




tested	   n	   Method	  used	  
Definition	  




expression	   Stage	  IIIC	  primary	  tumours	   41	   IHC	  –	  no	  quantification	  of	  intensity	   >20%	  of	  cells	  stain	  positive	   60.9	  
cMET	  expression	  associated	  with	  
higher	  grade	  tumours,	  more	  para-­‐
aortic	  lymph	  node	  involvement,	  and	  
worse	  overall	  survival.	   [30]	  
cMET	  over-­‐
expression	   EOC	  patients	  	   156	   IHC	  –	  intensity	  scale	  0-­‐3	   Intensity	  of	  3	   27.2	   cMET	  over-­‐expression	  was	  associated	  with	  an	  advanced	  tumour	  stage.	   [22]	  
cMET	  
expression	   Primary	  carcinoma	   67	   Southern	  and	  western	  blotting	   N/A	  
28%	  over-­‐expression	  by	  western,	  no	  amplification	  by	  Southern.	  
Expression	  was	  higher	  in	  lower-­‐
grade	  tumours.	  	  No	  correlation	  was	  
identified	  between	  cMET	  expression	  






Ovarian	  carcinomas	   119	   IHC	  –	  intensity	  x	  cellularity	   Score	  >6	   68	  
cMET	  over-­‐expression	  not	  correlated	  
with	  different	  histologic	  subtypes,	  
grades,	  nor	  tumour	  stages,	  
indicating	  that	  over-­‐expression	  may	  
be	  an	  early	  event.	   [26]	  
cMET	  over-­‐
expression	   Advanced	  stage	  ovarian	  cancers	   138	   IHC	  –	  intensity	  scale	  0-­‐3	   Intensity	  of	  3	   11	   cMET	  over-­‐expression	  correlated	  with	  poorer	  median	  survival.	   [25]	  
cMET	  
expression	   Malignant/borderline/benig 19	  (10/4/5)	   IHC	  –	  pixel	  intensity	  analysis	   N/A	   N/A	   Higher	  cMET	  expression	  in	  tumour	  vs	  OSE.	   [24]	  
	   15	  








Ovarian	  Cancer	  (adenocarcinoma/small	  cell/endometrioid)	  
40	  (36/1/3)	   IHC	  -­‐	  intensity	  	  scale	  0-­‐3	   Intensity	  1-­‐3	  
37%	  positive	  for	  HGF	  staining,	  30%	  positive	  for	  cMET	  expression,	  33%	  positive	  for	  P-­‐cMET.	  	  No	  mutations	  found.	  
N/A	   [27]	  
cMET	  
expression	   Primary	  ovarian	  carcinoma	   79	  
IHC	  -­‐	  intensity	  x	  cellularity,	  both	  0-­‐3	   Any	  signal	   92	  
No	  apparent	  association	  of	  cMET	  
expression	  with	  stage,	  response	  to	  
primary	  platinum	  therapy	  or	  CA125	  




expression	   Various	  
Varying	  depending	  on	  study	  
IHC	  –	  intensity	  x	  cellularity,	  and	  analysis	  of	  TCGA	  data	  
IHC	  –	  moderate-­‐strong	  in	  >10%	  of	  cells.	  
Moderate-­‐strong	  staining:	  HGF	  –	  83.3%,	  cMET	  –	  97.8%,	  P-­‐
HGF	  SNP	  rs1800793	  minor	  allele	  
associated	  with	  increased	  risk	  of	  
death.	  	  Stronger	  P-­‐cMET	  correlated	  
with	  decreased	  mortality	  (possibly	  
more	  highly	  expressed	  in	  early	  stage	  
disease).	  	  	  	  
[29]	  
	   16	  





Blood	  samples	  from	  women	  with	  pelvic	  masses,	  and	  surgical	  resection	  material	  
Blood	  –	  123,	  IHC	  -­‐	  81	   ELISA	  and	  IHC	  –	  cellularity	  0-­‐4	  scale	   N/A	   N/A	  
HGF	  >2	  SD	  above	  reference	  value	  
had	  s	  shorter	  disease-­‐free	  survival,	  
HGF	  higher	  in	  ovarian	  carcinoma	  
patients,	  than	  those	  with	  benign	  or	  




Cyst	  fluid,	  ascites,	  and	  peritoneal	  fluid	   52	   ELISA	   N/A	   N/A	  
Median	  HGF	  levels	  significantly	  
higher	  in	  ascites	  vs	  normal	  
peritoneal	  fluid.	  	  	   [32]	  
Met	  
amplificatio
n	   Archival	  FFPE	  samples	   110	   FISH	   MET:CEP7	  ratio	  >2	   4%	  
MET	  amplification	  associated	  with	  a	  
higher	  histological	  grade	  and	  
development	  of	  more	  metastatic	  






Clear	  cell	  ovarian	  carcinoma	   90	   FISH	  and	  IHC	  –	  intensity	  scale	  0-­‐3	  
FISH:	  MET:CEN7	  ratio,	  and	  %	  of	  cells	  positive	  for	  MET>CEN7.	  	  IHC:	  2-­‐3	  in	  
24%	  MET	  amplification,	  22%	  by	  IHC.	  
cMET	  over-­‐expression	  was	  identified	  
as	  an	  independent	  unfavourable	  
prognostic	  factor	  for	  overall	  survival.	  	  	   [43]	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>10%	  of	  cells	  
Met	  
amplificatio
n	  and	  cMET	  
over-­‐
expression	  
Clear	  cell	  ovarian	  carcinoma	   73	   FISH,	  qRT,	  and	  IHC	  
FISH:	  MET:CEP7	  ratio	  >2.	  	  qRT:	  MET/hTERT	  ratio	  >1.5.	  
37%	  MET	  amplification.	  
Stage	  1	  and	  2	  patients	  with	  Met	  
amplification	  had	  worse	  survival	  
than	  patients	  without	  Met	  
amplification.	   [44]	  
	  
Table	  1	  Publications addressing HGF/cMET biomarkers in ovarian cancer.  IHC, immunohistochemistry.  FISH, fluorescent in situ 
hybridisation.  qRT, quantitative reverse transcriptase PCR.  SNP, single nucleotide polymorphism.  ELISA, enzyme-linked immunosorbent 
assay.
	   18	  
	   19	  
Agent	   Other	  names	   Company	   Type	   Target/s	   In	  clinical	  trial/s	  
(past	  and	  present)	  
Trials	  using	  
biomarkers	  ABT-­‐700	   h224G11	   AbbVie	   mAb	   cMET	   Yes,	  1	  listed	   	  AMG	  208	   	   Amgen	   TKI	   cMET,	  Ron	   Yes,	  2	  listed	   NCT00813384	  	  AMG	  337	   	   Amgen	   TKI	   cMET	   Yes,	  4	  listed	  	   NCT02344810	  NCT02016534	  NCT02096666	  ARGX-­‐111	   	   arGEN-­‐x	   mAb	   cMET	   Yes,	  1	  listed	   NCT02055066	  	  BMS-­‐777607	   ASLAN002	   ASLAN	  pharmaceuticals,	  BMS	   TKI	   cMET,	  RON,	  AXL	   Yes,	  2	  listed	   	  BMS-­‐794833	   	   BMS	   TKI	   cMET,	  AXL,	  FLT3,	  RON,	  VEGFR2	   1,	  withdrawn.	   	  Cabozantinib	   XL	  184,	  BMS907351	   Exelixis,	  BMS	   TKI	   cMET,	  VEGFR2,	  RET,	  KIT,	  FLT3,	  Tie2	   	  	  	  Yes,	  68	  listed	  
NCT02008383	  NCT01553656	  NCT01639508	  	  CGEN-­‐241	   	   Compugen	   Decoy	  cMET	   	   None	  listed.	   	  Crizotinib	   PF02341066,	  Xalkori	   Pfizer	   TKI	   cMET,	  ROS1,	  ALK,	  AXL,	  RON,	  Tie2	   Yes,	  88	  listed	   NCT02034981	  NCT02499614	  NCT01524926	  NCT02435108	  NCT02510001	  NCT02612194	  	  
	   20	  
E-­‐7050	   Golvantinib	   Eisai	   TKI	   cMET,	  VEGFR2	   Yes,	  8	  listed	   	  EMD	  1204831	   	   EMD	  Serono	   TKI	   cMET	   1,	  terminated	   	  EMD-­‐1214063	   Tepotinib,	  MSC2156119J	   EMD	  Serono	   TKI	   cMET	   Yes,	  1.	   	  Ficlatuzumab	   AV-­‐299,	  SCH900105	   AVEO	   mAb	   HGF	   Yes,	  7	  listed	   NCT02277184	  NCT02277197	  	  Foretinib	   XL	  880,	  GSK1363089	   Exelixis,	  GSK	   TKI	   cMET,	  VEGFR2,	  AXL,	  PDGFR,	  Kit,	  Tie2,	  FLT3	   Yes,	  11	  listed	   NCT00725764	  NCT00725712	  NCT01147484	  	  INC280	   INCB28060,	  Capmatinib	   Incyte,	  Novartis	   TKI	   cMET	   Yes,	  21	  listed	   NCT01870726	  NCT01737827	  NCT02468661	  NCT01964235	  NCT02626234	  NCT02520752	  NCT01610336	  NCT02276027	  NCT02205398	  NCT02323126	  NCT02414139	  NCT01324479	  NCT01911507	  JNJ-­‐38877605	   	   Johnson	  &	  Johnson	   TKI	   cMET	   Yes,	  1	  listed	   	  LY-­‐2801653	   Merestinib	   Eli	  Lilly	   TKI	   cMET,	  VEGFR2,	  RON,	  FLT3,	  AXL	   Yes,	  3	  listed	   	  
	   21	  
LY-­‐2875358	   Emibetuzumab	   Eli	  Lilly	   mAb	   cMET	   Yes,	  6	  listed	   NCT01900652	  NCT01874938	  MGCD-­‐265	   	   Methylgene	   TKI	   cMET,	  RON,	  VEGFER1,	  VEGFR2,	  VEGFR3,	  Tie2.	   Yes,	  6	  listed	   NCT02544633	  NCT00697632	  	  MK	  8033	   	   Merck	   TKI	   cMET,	  RON	   Yes,	  1	  listed	   NCT00559182	  MK-­‐2461	   	   Merck	   TKI	   cMET,	  RON,	  Flt	  1/3,	  PDGFRβ	   Yes,	  2	  listed	   	  MP470	   Amuvatinib	   SuperGen	   TKI	   cMET,	  cKit,	  PDGFR,	  FLT3,	  AXL	   Yes,	  4	  listed	   	  MSC2156119J	   EMD	  1214063,	  Tepotinib	   Merck,	  EMD	  Serono	   TKI	   cMET	   Yes,	  5	  listed	   NCT01832506	  NCT01014936	  NCT01982955	  NCT01988493	  NCT02115373	  NK4	   	   Kringle	  Pharma	   HGF	  antagonist	   	   None	  listed	   	  NVP-­‐BVU972	   	   Novartis	   TKI	   cMET	   None	  listed	   	  Onartuzumab	   OA5D5,	  MetMab,	  RO5490258	   Genentech,	  Roche	   mAb	  	   cMET	   Yes,	  17	  listed	   NCT01974258	  NCT01519804	  NCT01632228	  NCT02044601	  NCT01590719	  NCT01662869	  NCT01887886	  NCT02031744	  NCT01496742	  
	   22	  
NCT01456325	  NCT00854308	  PF-­‐04217903	   	   Pfizer	   TKI	   cMET,	  ALK	   1,	  terminated.	   	  PHA-­‐665752	   	   Pfizer	   TKI	   cMET	   None	  listed	   	  Rilotumumab	   AMG	  102	   Amgen	   mAb	   HGF	   Yes,	  15	  listed	   NCT02137343	  NCT01039207	  NCT01697072	  NCT00422019	  NCT02154490	  Sar125844	   	   Sanofi	   TKI	   cMET	   Yes,	  3	  listed	   NCT01657214	  NCT01391533	  NCT02435121	  SGX-­‐523	   	   SGX	  Pharmaceuticals	   TKI	   cMET	   2,	  both	  terminated	   	  SU11274	   	   Sugen	   TKI	   cMET	   None	  listed	   	  TAK-­‐701	   	   Millennium	   mAb	   HGF	   Yes,	  1	  listed	   	  Tas	  115	   	   Taiho	   TKI	   cMET,	  VEGFR	   None	  listed	   	  Tivantinib	   ARQ197	   ArQule,	  Daiichi	  Sankyo	   TKI,	  non-­‐ATP	  competitive	  
cMET	   Yes,	  46	  listed	   NCT01447914	  NCT01749384	  NCT01395758	  NCT01625156	  NCT01725191	  NCT01892527	  NCT01696955	  NCT01688973	  NCT01244191	  NCT01755767	  
	   23	  
NCT01861301	  NCT01575522	  NCT00612209	  NCT00777309	  NCT00874042	  NCT00827177	  NCT00802555	  NCT01468922	  NCT02029157	  Volitinib	   HMPL-­‐504,	  AZD6094,	  Savolitinib	   Hutchison	  Medipharma	  Limited	  	   TKI	   cMET	   Yes,	  9	  listed	   NCT02252913	  NCT02374645	  NCT02449551	  NCT01773018	  NCT02447406	  NCT02447380	  	  
Table 2.  Agents targeting HGF/cMET.  mAb, monoclonal antibody.  TKI, tyrosine kinase inhibitor.  BMS, Bristol-Myers Squibb.  GSK, 
GlaxoSmithKline.















Table 3.  Agents targeting HGF/cMET in ovarian cancer-specific clinical trials, 
and publications describing disease results. 
 
 
Agent	   Clinical	  trials	  targeted	  at	  
patients	  with	  ovarian	  
cancer	  
Publications	  specifying	  results	  
for	  patients	  with	  ovarian	  cancer	  AMG	  208	   -­‐	   [99]	  Cabozantinib	   NCT01716715	  NCT02315430	   Buckanovich et al, ASCO 2011, abstract 5008	  Ficlatuzumab	   NCT02090127,	  continued	  access	   [61]	  Onartuzumab	   -­‐	   [100]	  Rilotumumab	   NCT01039207	   [71,	  88]	  Tivantinib	   -­‐	   [97,	  98,	  101]	  
	   25	  
References. 1.	   Siegel	   RL,	   Miller	   KD,	   Jemal	   A.	   Cancer	   statistics,	   2015.	   CA	   Cancer	   J	   Clin.	  2015;65(1):5-­‐29.	  doi:10.3322/caac.21254.	  2.	  Kurman	  RJ.	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   and	  molecular	  pathogenesis	   of	   ovarian	  high-­‐grade	   serous	  carcinoma.	  Ann	  Oncol.	  2013;24	  Suppl	  10:x16-­‐21.	  doi:10.1093/annonc/mdt463.	  3.	   Kurman	   RJ,	   Shih	   Ie	   M.	   Molecular	   pathogenesis	   and	   extraovarian	   origin	   of	  epithelial	   ovarian	   cancer-­‐-­‐shifting	   the	   paradigm.	   Hum	   Pathol.	   2011;42(7):918-­‐31.	  doi:10.1016/j.humpath.2011.03.003.	  4.	  Gershenson	  DM,	  Sun	  CC,	  Lu	  KH,	  Coleman	  RL,	  Sood	  AK,	  Malpica	  A	  et	  al.	  Clinical	  behavior	  of	  stage	  II-­‐IV	  low-­‐grade	  serous	  carcinoma	  of	  the	  ovary.	  Obstet	  Gynecol.	  2006;108(2):361-­‐8.	  doi:10.1097/01.AOG.0000227787.24587.d1.	  5.	   Lengyel	   E.	   Ovarian	   cancer	   development	   and	   metastasis.	   Am	   J	   Pathol.	  2010;177(3):1053-­‐64.	  doi:10.2353/ajpath.2010.100105	  S0002-­‐9440(10)60160-­‐5	  [pii].	  6.	  Panici	  PB,	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  Salerno	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  A,	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  L,	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   cancer:	   surgical	   and	   survival	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   a	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   series.	   Ann	   Surg	   Oncol.	   2014;21(9):3036-­‐41.	  doi:10.1245/s10434-­‐014-­‐3714-­‐6.	  7.	  Anglesio	  MS,	  George	  J,	  Kulbe	  H,	  Friedlander	  M,	  Rischin	  D,	  Lemech	  C	  et	  al.	  IL6-­‐STAT3-­‐HIF	   signaling	   and	   therapeutic	   response	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   the	   angiogenesis	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  sunitinib	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   Clin	   Cancer	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  10.1158/1078-­‐0432.CCR-­‐08-­‐0196.	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   Genome	   Atlas	   Research	   N.	   Integrated	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  Nature.	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  IV	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  cancer.	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  Engl	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